Franklin Resources Inc. Buys 60,397 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Franklin Resources Inc. increased its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 706,106 shares of the company’s stock after purchasing an additional 60,397 shares during the period. Franklin Resources Inc. owned approximately 1.23% of Structure Therapeutics worth $30,991,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GPCR. Geode Capital Management LLC boosted its position in Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after purchasing an additional 312 shares during the last quarter. Barclays PLC raised its position in Structure Therapeutics by 64.5% during the third quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after purchasing an additional 31,815 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 35.6% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 29,429 shares of the company’s stock worth $1,292,000 after acquiring an additional 7,719 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Structure Therapeutics during the third quarter valued at about $1,787,000. Finally, Pier Capital LLC boosted its stake in shares of Structure Therapeutics by 32.7% during the third quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock valued at $5,894,000 after purchasing an additional 33,087 shares during the period. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Trading Down 11.4 %

NASDAQ GPCR opened at $27.90 on Thursday. The company has a fifty day simple moving average of $35.71 and a two-hundred day simple moving average of $39.09. The stock has a market cap of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41. Structure Therapeutics Inc. has a 12-month low of $26.23 and a 12-month high of $62.74.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target on the stock. HC Wainwright started coverage on Structure Therapeutics in a research report on Wednesday, December 4th. They issued a “buy” rating and a $80.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $86.50.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.